CombiMatrix Corp (NASDAQ:
CBMX): Granted
approval for
pre-implantation
genetic screening and conditional approval from NYS Department of Health.
CytRx Corporation (NASDAQ:
CYTR):
Announced
Aldoxorubicin achieved primary endpoint, stating, “Statistically significant improvement in progression-free survival in
patients with Liposarcoma." The company expects to submit an NDA with the FDA for Aldoxorubicin as treatment for patients with
relapsed or refractory STS in 2017.
Dimension Therapeutics Inc (NASDAQ:
DMTX)
Received
positive opinion for DTX401 for European orphan drug designation.
KemPharm Inc (NASDAQ:
KMPH):
Received
FDA clearance to initiate KP201/IR trial.
Momenta Pharmaceuticals, Inc. (NASDAQ:
MNTA): Announced Phase III for M923 met
primary
endpoint and all secondary endpoints.
Novan Inc (NASDAQ:
NOVN): Announced Phase II trial
achieved significant results.
Vascular Biogenics Ltd (NASDAQ:
VBLT):
Announced
VB-111 met primary endpoint, stating, "[It] shows evidence of overall survival rate."
All data compiled using Benzinga Pro.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.